Advice
Following a resubmission
etonogestrel / ethinylestradiol vaginal ring (NuvaRing) is accepted for use within NHS Scotland for contraception.
Results from two randomised phase III clinical studies indicate that the contraceptive efficacy of NuvaRing® is similar to that of two combined oral contraceptives. NuvaRing® produces good cycle control and user acceptability. Cost-effectiveness has been demonstrated in women who chose to discontinue oral contraceptives. Other non-oral contraceptives are available at lower cost.
Download detailed advice99KB (PDF)
Medicine details
- Medicine name:
- etonogestrel (Nuvaring)
- SMC ID:
- 502/08
- Indication:
- Contraception
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 12 October 2009